FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns a method for assessing the fact if a pregnant woman suffers from a high risk of preeclampsia, consisting in the fact of using a monoclonal body reactive on H2-relaxin, measuring the H2-relaxin concentration in a biological sample taken from the pregnant woman before a preeclampsia symptom is manifested, wherein the monoclonal antibody is produced with using a hybridoma deposited in the American type culture collection No. PTA-8423; stating that the pregnant woman suffers from the high risk of preeclampsia, if the H2-relaxin concentration is less than a lower concentration quartile limit specific for the pregnant woman; a method for establishing the diagnosis of preeclampsia; a method for relieving preeclampsia.
EFFECT: group of inventions makes it possible to assess the high risk of preeclampsia and establishing the related diagnosis.
10 cl, 3 ex, 6 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF AQUAPORINS WITH RELAXIN | 2011 |
|
RU2564900C2 |
| METHOD FOR PREVENTING PREMATURE DELIVERY | 2009 |
|
RU2501573C2 |
| METHOD OF PREDICTING SEVERE PRE-ECLAMPSIA | 2014 |
|
RU2568892C1 |
| METHOD OF PREDICTING DEVELOPMENT OF PRE-ECLAMPSIA IN WOMEN WITH NON-BURDENED HEREDITY | 2014 |
|
RU2568893C1 |
| METHOD FOR PREDICTION OF RISK OF PREECLAMPSIA DEVELOPMENT IN WOMEN DEPENDING ON HEREDITARY BURDEN | 2016 |
|
RU2646455C1 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| METHOD OF TREATING CHRONIC CARDIAL FAILURE | 2009 |
|
RU2512933C2 |
| APPLICATION OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES SUCH AS TYPE 2 DIABETES | 2010 |
|
RU2566264C2 |
| USE OF LACTIC ACID BACTERIA FOR TREATING OR PREVENTING GESTATIONAL DIABETES MELLITUS | 2017 |
|
RU2769312C2 |
| METHOD OF PREDICTING PREECLAMPSIA THERAPY EFFICIENCY | 2011 |
|
RU2475753C1 |
